ABOS: Acumen Pharmaceuticals Inc. Stocks News on May 15, 2025

ABOS

GuruFocus.com

a day ago

Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

ABOS

Thomson Reuters StreetEvents

a day ago

Q1 2025 Acumen Pharmaceuticals Inc Earnings Call

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

ABOS

GlobeNewswire

2 days ago

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

ABOS

GlobeNewswire

8 days ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

ABOS

GlobeNewswire

9 days ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

ABOS

GlobeNewswire

a month ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

ABOS

GlobeNewswire

a month ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

ABOS

MT Newswires

2 months ago

UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating

ABOS

GuruFocus.com

2 months ago

Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ...

ABOS

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Acumen Pharmaceuticals Inc Earnings Call

Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s

ABOS

Clinical Trials Arena

2 months ago

Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

ABOS

GlobeNewswire

2 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Promising US Penny Stocks To Consider In January 2025

ABOS

Simply Wall St.

4 months ago

Promising US Penny Stocks To Consider In January 2025

Acumen announces Phase 1 INTERCEPT-AD study publication

ABOS

TipRanks

4 months ago

Acumen announces Phase 1 INTERCEPT-AD study publication

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

ABOS

GlobeNewswire

4 months ago

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

I-Mab Leads Our Spotlight On 3 US Penny Stocks

ABOS

Simply Wall St.

5 months ago

I-Mab Leads Our Spotlight On 3 US Penny Stocks

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

ABOS

GuruFocus.com

6 months ago

Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

ABOS

Thomson Reuters StreetEvents

6 months ago

Q3 2024 Acumen Pharmaceuticals Inc Earnings Call

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

ABOS

GlobeNewswire

6 months ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ABOS

GlobeNewswire

7 months ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

3 US Penny Stocks With Market Caps Under $500M To Consider

ABOS

Simply Wall St.

7 months ago

3 US Penny Stocks With Market Caps Under $500M To Consider

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

ABOS

GlobeNewswire

7 months ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

ABOS

MT Newswires

8 months ago

Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

ABOS

GlobeNewswire

8 months ago

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

ABOS

GlobeNewswire

8 months ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

ABOS

GlobeNewswire

8 months ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

ABOS

MT Newswires

9 months ago

UBS Lowers Price Target on Acumen Pharmaceuticals to $6 From $14, Maintains Buy Rating

ABOS

Thomson Reuters StreetEvents

9 months ago

Q2 2024 Acumen Pharmaceuticals Inc Earnings Call

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

ABOS

GlobeNewswire

9 months ago

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

ABOS

GlobeNewswire

9 months ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

ABOS

MT Newswires

10 months ago

Acumen Pharmaceuticals Doses First Person in Phase 1 Study of Sabirnetug for Alzheimer's Disease

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

ABOS

GlobeNewswire

10 months ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

ABOS

MT Newswires

10 months ago

Acumen Pharmaceuticals Says Alzheimer's Therapy Phase 1 Results Consistent With Proposed Mechanism of Action

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

ABOS

GlobeNewswire

10 months ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

ABOS

MT Newswires

10 months ago

Citigroup Starts Acumen Pharmaceuticals With Buy Rating, $7 Price Target

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

ABOS

GlobeNewswire

10 months ago

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

ABOS

Insider Monkey

a year ago

Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?

ABOS

GuruFocus.com

a year ago

Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

ABOS

Thomson Reuters StreetEvents

a year ago

Q1 2024 Acumen Pharmaceuticals Inc Earnings Call

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

ABOS

MT Newswires

a year ago

Arthur J. Gallagher Acquires Acumen Advisors

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

ABOS

MT Newswires

a year ago

Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By

ABOS

Insider Monkey

a year ago

12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

ABOS

Insider Monkey

a year ago

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment

ABOS

Exec Edge

a year ago

Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

ABOS

Zacks

a year ago

Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick

ABOS

Zacks

a year ago

Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?

ABOS

Insider Monkey

a year ago

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript

ABOS

Thomson Reuters StreetEvents

a year ago

Q4 2023 Acumen Pharmaceuticals Inc Earnings Call

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

ABOS

Zacks

a year ago

Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

15 Best Anti-Aging Foods for Youthful Skin

ABOS

Insider Monkey

a year ago

15 Best Anti-Aging Foods for Youthful Skin

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

ABOS

Zacks

a year ago

Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?

ABOS

Simply Wall St.

a year ago

Institutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

ABOS

GlobeNewswire

a year ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot

ABOS

InvestorPlace

a year ago

Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot

PEOPLES FINANCIAL SERVICES CORP. Declares First Quarter 2024 Dividend

ABOS

PR Newswire

a year ago

PEOPLES FINANCIAL SERVICES CORP. Declares First Quarter 2024 Dividend

BrightView Publishes 2024 Corporate Responsibility Report

ABOS

Business Wire

a year ago

BrightView Publishes 2024 Corporate Responsibility Report

The Fed Tells Banks Not to Be Shy About Asking It for Money

ABOS

Bloomberg

a year ago

The Fed Tells Banks Not to Be Shy About Asking It for Money

Bridgewater Bancshares Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

ABOS

Simply Wall St.

a year ago

Bridgewater Bancshares Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

BayCom Corp (BCML) Reports Decrease in Q4 Earnings Amidst Market Challenges

ABOS

GuruFocus.com

a year ago

BayCom Corp (BCML) Reports Decrease in Q4 Earnings Amidst Market Challenges

CORRECTION: Summit Financial Group Reports Earnings of $1.11 Per Share for Fourth Quarter 2023

ABOS

GlobeNewswire

a year ago

CORRECTION: Summit Financial Group Reports Earnings of $1.11 Per Share for Fourth Quarter 2023

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

ABOS

Zacks

a year ago

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom

ABOS

InvestorPlace

a year ago

3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom

ABOS

GuruFocus.com

a year ago

FVCBankcorp Inc (FVCB) Reports Mixed Results Amidst Strategic Repositioning

Aragon Research positions LivePerson as a Leader in The Aragon Research Globe™ Report for Conversational AI, 2024

ABOS

PR Newswire

a year ago

Aragon Research positions LivePerson as a Leader in The Aragon Research Globe™ Report for Conversational AI, 2024

FVCBankcorp (FVCB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ABOS

Zacks

a year ago

FVCBankcorp (FVCB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ABOS

Associated Press Finance

a year ago

FVCBankcorp: Q4 Earnings Snapshot

FVCBankcorp, Inc. Announces 2023 Earnings

ABOS

Business Wire

a year ago

FVCBankcorp, Inc. Announces 2023 Earnings

LivePerson (LPSN) Opts for Net Operating Loss Rights Plan

ABOS

Zacks

a year ago

LivePerson (LPSN) Opts for Net Operating Loss Rights Plan

Kopin Receives Initial Production Order for Advanced Surgical Information Display

ABOS

Business Wire

a year ago

Kopin Receives Initial Production Order for Advanced Surgical Information Display

ABOS

Associated Press Finance

a year ago

RBB: Q4 Earnings Snapshot

RBB Bancorp Reports Fourth Quarter and Fiscal Year 2023 Earnings

ABOS

Business Wire

a year ago

RBB Bancorp Reports Fourth Quarter and Fiscal Year 2023 Earnings

17 Best Augmented Reality Stocks To Invest In

ABOS

Insider Monkey

a year ago

17 Best Augmented Reality Stocks To Invest In

Sify Technologies Limited (NASDAQ:SIFY) Q3 2024 Earnings Call Transcript

ABOS

Insider Monkey

a year ago

Sify Technologies Limited (NASDAQ:SIFY) Q3 2024 Earnings Call Transcript

ABOS

Zacks

a year ago

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron

Renovaro BioSciences Releases CEO Shareholder Message

ABOS

NewMediaWire

a year ago

Latest Acumen Pharmaceuticals Inc. (ABOS) News on May 15, 2025

Share on Social Networks: